Predicting the costs of allogeneic sibling stem-cell transplantation: Results from a prospective, multicenter, French study

Transplantation

Volumn 77, Issue 12, 2004, Pages 1854-1858

  Espérou, Hélène ^a   Brunot, Alain ^b   Roudot Thoraval, Françoise ^b   Buzyn, Agnes ^c   Dhedin, Nathalie ^d   Rio, Bernard ^e   Chevret, Sylvie ^a   Bassompierre, François ^f   Gluckman, Eliane ^a   Cordonnier, Catherine ^b   Durand Zaleski, Isabelle ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADULT; ALLOTRANSPLANTATION; AMBULATORY CARE; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE PAYMENT; PROSPECTIVE STUDY; SCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHRONIC DISEASE; COSTS AND COST ANALYSIS; FEMALE; FRANCE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INFECTION; LEUKEMIA; MALE; MIDDLE AGED; PLACEBOS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 3042569758     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000129409.84087.62     Document Type: Article

References (14)

1. Cordonnier C, Chevret S, Legrand M, et al., for the GREFIG Study Group. Should immunoglobulin therapy be used in allogeneic transplant? Results of a randomized, dose-effect, placebo-controlled, double blind, multicenter trial. Ann Intern Med 2003; 139: 8-18.
2. Lee SJ, Klar N, Weeks JC, et al. Predictive costs of stem cell transplantation. J Clin Oncol 2000 18: 64-71.
3. Armitage J. Bone marrow transplantation. N Engl J Med 1994; 330: 827-838.
4. Shulman H, Sullivan K, Weiden P, et al. Chronic graft-versus-host syndrome in man: a long term clinico-pathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
5. McDonald G, Sharma P, Matthews D, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation. Ann Intern Med 1993; 118: 255-267.
6. Lungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin S, eds. Multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Experta Medica International Congress Series 1993, pp. 233-237.
7. Raikpou M, Briggs A, Gray A, et al. Center-specific or average unit costs from multi-center studies? Some theory and simulation. Health Econ 2000; 9: 191-198.
8. Thompson SG, Barber JA. How should cost data in pragmatic randomized trials be analyzed? BMJ 2000; 320: 1197-1200.
9. Mishra V, Vaaler S, Brinch L. A prospective cost evaluation related to allogeneic hematopoietic stem cell transplantation including pre-transplant procedures, transplantation and 1-year follow-up procedures. Bone Marrow Transplant 2001: 28 1111-1116.
10. Waters TM, Bennett CL, Pajeau TS, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant 1998; 21: 641-650.
11. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myeloid leukemia or acute lymphoblastic leukemia. Bone Marrow Transplant 2002; 30: 243-251.
12. Kline RM, Meiman S, Tarentino MD, et al. A detailed analysis of charges for hematopoietic stem cell transplantation at a children's hospital. Bone Marrow Transplant 1998; 21: 195-203.
13. Bennett CL, Waters TM, Stinson TJ, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 555-560.
14. Przepiorka D, Smith TL, Folloder J, et al. Controlled trial of filgrastim for acceleration neutrophil recovery after allogeneic blood stem cell transplantation from HLA matched related donors. Blood 2001; 97: 3405-3410.